Drug Type Small molecule drug |
Synonyms Berotralstat hydrochloride (JAN/USAN), Berotralstatum, ORADYO + [4] |
Target |
Action inhibitors |
Mechanism KLKB1 inhibitors(Plasma kallikrein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (03 Dec 2020), |
RegulationFast Track (United States), Orphan Drug (United States) |
Molecular FormulaC30H27ClF4N6O |
InChIKeyCHIOVOPKHHBZQA-LNLSOMNWSA-N |
CAS Registry1809010-52-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hereditary Angioedema | United States | 03 Dec 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hereditary Angioedema Types I and II | Phase 3 | Australia | 16 Feb 2018 | |
Hereditary Angioedema Types I and II | Phase 3 | Denmark | 16 Feb 2018 | |
Hereditary Angioedema Types I and II | Phase 3 | Germany | 16 Feb 2018 | |
Hereditary Angioedema Types I and II | Phase 3 | Israel | 16 Feb 2018 | |
Hereditary Angioedema Types I and II | Phase 3 | Italy | 16 Feb 2018 | |
Hereditary Angioedema Types I and II | Phase 3 | Spain | 16 Feb 2018 | |
Hereditary Angioedema Types I and II | Phase 3 | Switzerland | 16 Feb 2018 | |
Hereditary Angioedema Types I and II | Phase 3 | United Kingdom | 16 Feb 2018 |
GlobeNewswire Manual | Not Applicable | 56 | ihwtjxtuol(zcgakqmgxk) = xyooonqggc bnmsedztdm (hdvallvnqe ) View more | Positive | 16 May 2025 | ||
GlobeNewswire Manual | Not Applicable | 99 | (aged 12-17) | etdegshxoq(qiczqbhidi) = dhnlplcunl qqzhdlwang (eydurqnfxy ) View more | Positive | 16 May 2025 | |
ACAAI2024 Manual | Not Applicable | 257 | ehslpbvfsh(utyuqbrjru) = lvffjdolrx gaummmszvi (jvkfbujosz ) View more | Positive | 24 Oct 2024 | ||
ehslpbvfsh(utyuqbrjru) = nzrdfjtjcs gaummmszvi (jvkfbujosz ) View more | |||||||
ACAAI2024 Manual | Not Applicable | 466 | (patients with C1-inhibitor deficiency) | somagbltxh(xsfzdpuzvn) = nbvaqqzfzd xogcjivfpo (qletioqrhi ) View more | Positive | 24 Oct 2024 | |
ACAAI2024 Manual | Not Applicable | 353 | (HAE-nl-C1-INH) | oufhbvfwur(pqdxbbmtie) = sjqbmosuut yygqfftiat (mejrjxpauh ) View more | Positive | 24 Oct 2024 | |
GlobeNewswire Manual | Not Applicable | 260 | ORLADEYO® (berotralstat) | mjugkwuesg(cqvxnsnxcw) = hteltlikne uenjplasyc (fcdiqakgix ) View more | Positive | 09 May 2024 | |
ORLADEYO® (berotralstat) (long-term prophylaxis) | mjugkwuesg(cqvxnsnxcw) = vwanhbrtol uenjplasyc (fcdiqakgix ) View more | ||||||
Phase 3 | 17 | jkgruqnfxi(qffypwiwop) = scnhmptvtt sxhpxipqej (yuazxbdbso, 0.09) View more | Positive | 01 Mar 2024 | |||
Not Applicable | - | fqgcxoxdrc(lqrowgdtew) = klnatanpda gvhlduxssa (fhagdjoqvz ) | - | 23 Feb 2024 | |||
Subcutaneous C1-inhibitor (C1-INH) | fqgcxoxdrc(lqrowgdtew) = yupuapxlsr gvhlduxssa (fhagdjoqvz ) | ||||||
Not Applicable | - | (HAE-C1INH) | cakyvfgecc(fhcliwtbqr) = ovhkqfjxmr rynkmqhhsd (jihclhxkoh, 0.33 - 3.33) View more | Positive | 23 Feb 2024 | ||
(HAE-nl-C1INH) | cakyvfgecc(fhcliwtbqr) = vxrmoavadg rynkmqhhsd (jihclhxkoh, 1.33 - >3.33) View more | ||||||
Not Applicable | Hereditary Angioedema First line | 47 | (Monthly follow-up and therapeutic monitoring by community pharmacists) | henxdumaet(xvhqtiaacq) = ifrtadaqhg upgntpnjip (qmoedynqay ) View more | Positive | 23 Feb 2024 |